Literature DB >> 2783595

Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy.

M Grover-McKay1, M Schwaiger, J Krivokapich, J K Perloff, M E Phelps, H R Schelbert.   

Abstract

Previous observations and clinical manifestations suggest the presence of ischemia in the disproportionately thickened septum of patients with hypertrophic cardiomyopathy. Metabolic consequences of ischemia can be demonstrated with positron emission tomography. Therefore, 10 patients with hypertrophic cardiomyopathy and an echocardiographic septum to posterior wall thickness ratio of 1.8 +/- 0.4 cm (range 1.3 to 2.5) were studied with the use of nitrogen (N)-13 ammonia, carbon (C)-11 palmitate and fluoro (F)-18 2-deoxyglucose as tracers of myocardial blood flow, fatty acid metabolism and exogenous glucose utilization. The results of positron emission tomography in 9 patients with hypertrophic cardiomyopathy were compared with those in 10 normal volunteers. In the hypertrophic cardiomyopathy group, observed myocardial activity of N-13 ammonia and C-11 palmitate in the septum was similar to that in the lateral wall. Septum to lateral wall tissue activity ratios averaged 1.04 +/- 0.15 for N-13 ammonia and 1.04 +/- 0.18 for C-11 palmitate, and were similar to those in the normal volunteers (0.98 +/- 0.07 and 0.98 +/- 0.03, respectively; p = NS). Myocardial clearance half-time and residual fraction of C-11 palmitate did not differ significantly between the septum and lateral wall. However, F-18 2-deoxyglucose uptake was significantly lower in the septum than in the lateral wall (15,768 +/- 4,314 versus 19,818 +/- 5,234 counts/pixel; p less than 0.003). The mean septum to lateral wall activity ratio of 0.83 +/- 0.21 was less than that observed in normal volunteers (0.92 +/- 0.07; p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783595     DOI: 10.1016/0735-1097(89)90505-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

Review 1.  Future aspects of BMIPP.

Authors:  N Tamaki; K Morita; E Tsukamoto; Y Kawai
Journal:  Int J Card Imaging       Date:  1999-02

Review 2.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

3.  Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.

Authors:  Paul Knaapen; Willem G van Dockum; Marco J W Götte; Kimiko A Broeze; Joost P A Kuijer; Jaco J M Zwanenburg; J Tim Marcus; Wouter E M Kok; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 4.  Complementarity of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography for the in vivo investigation of human cardiac metabolism and neurotransmission.

Authors:  A Syrota; P Jehenson
Journal:  Eur J Nucl Med       Date:  1991

5.  Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy.

Authors:  J L Posma; P K Blanksma; E E Van Der Wall; W Vaalburg; H J Crijns; K I Lie
Journal:  Heart       Date:  1996-10       Impact factor: 5.994

Review 6.  Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.

Authors:  Valentin Fuster; Sarina van der Zee; Marc A Miller
Journal:  J Cardiovasc Transl Res       Date:  2009-10-16       Impact factor: 4.132

7.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

8.  Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI.

Authors:  Tohoru Takeda; Jin Wu; Yuko Fumikura; Keiji Iida; Satoru Kawano; Iwao Yamaguchi; Yuji Itai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-20       Impact factor: 9.236

9.  Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study.

Authors:  Helena Tuunanen; Johanna Kuusisto; Jyri Toikka; Pertti Jääskeläinen; Päivi Marjamäki; Keijo Peuhkurinen; Tapio Viljanen; Petri Sipola; Kira Q Stolen; Jarna Hannukainen; Pirjo Nuutila; Markku Laakso; Juhani Knuuti
Journal:  J Nucl Cardiol       Date:  2007-05-10       Impact factor: 5.952

10.  Is I-123-beta-methyl-p-iodophenyl-methylpentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? I-123 BMIPP imaging to evaluate asymptomatic hypertrophic cardiomyopathy.

Authors:  Michihiro Narita; Tadashi Kurihara
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.